Literature DB >> 14631275

[The French national waiting list for keratoplasty created in 1999: patient registration, indications, characteristics, and turnover].

C Poinard1, P Tuppin, B Loty, B Delbosc.   

Abstract

PURPOSE: To evaluate the French waiting list and the indications of registered patients, to compare the rates of registration, graft, and procurement between French regions.
METHODS: In France, each patient with an indication for penetrating keratoplasty should be registered on the waiting list with his or her clinical characteristics. Those registered during 2000 and 2001 were included in the study. Data on transplantation activity from the waiting list were compared to data collected by a questionnaire on graft and procurement activities completed each year by medical teams.
RESULTS: In 2000 and 2001, 6093 and 5505 waiting patients, respectively, were registered. For the same years, 3984 and 3457 keratoplasties were declared for the patients registered, but the questionnaires reported 4514 and 4388 grafts, respectively. The national registration rate was 96 per million population (pmp). The extreme values between regions ranged from 53 to 143 pmp. There was a significant correlation between regional procurement and transplantation rates (r=0.75, p=0.001) but not for registration and procurement rates, and not for registration and transplantation rates. The national registration rate was 27 pmp for pseudophakic and aphakic corneal edema, with extreme values of 12-64 pmp. The national registration rate was 24 pmp for keratoconus (11-37 pmp). A high patient turnover was observed between regions. Among the 11,598 patients registered, the most common indications were pseudophakic and aphakic corneal edema (27.7%), keratoconus (25.3%), and Fuchs'endothelial dystrophy (9.1%). Mean recipient age was 57+/-22 years (0-103 years). Among these patients, 14.1% had already received transplants at least once for the same eye (7.8% for keratoconus, 14.3% for pseudophakic and aphakic corneal edema, and 6.1% for Fuchs'dystrophy). DISCUSSION: Ophthalmologists will be able to register their patients directly on the waiting list, which will improve data quality for transplantation notification. Regional policies should be developed to decrease the inequalities of graft shortages between regions.

Entities:  

Mesh:

Year:  2003        PMID: 14631275

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  7 in total

1.  Fuchs' corneal dystrophy.

Authors:  Allen O Eghrari; John D Gottsch
Journal:  Expert Rev Ophthalmol       Date:  2010-04

2.  Efficiency of blood culture bottles for the fungal sterility testing of corneal organ culture media.

Authors:  G Thuret; A Carricajo; A C Vautrin; H Raberin; S Acquart; O Garraud; P Gain; G Aubert
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

3.  Indications of penetrating keratoplasty in southern India.

Authors:  Laxman Dasar; Chaitra Pujar; Kanwarpal Singh Gill; Madhuri Patil; Mallikarjun Salagar
Journal:  J Clin Diagn Res       Date:  2013-11-10

4.  Trends in the indications for penetrating keratoplasty in Shandong, 2005-2010.

Authors:  Jun-Yi Wang; Li-Xin Xie; Xiu-Sheng Song; Jing Zhao
Journal:  Int J Ophthalmol       Date:  2011-10-18       Impact factor: 1.779

5.  Impact of new lamellar techniques of keratoplasty on eye bank activity.

Authors:  Marc Muraine; David Toubeau; Julie Gueudry; Gerard Brasseur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-10       Impact factor: 3.117

6.  Prevalence and associations of steep cornea/keratoconus in Greater Beijing. The Beijing Eye Study.

Authors:  Liang Xu; Ya Xing Wang; Yin Guo; Qi Sheng You; Jost B Jonas
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

7.  In Vivo Functionality of a Corneal Endothelium Transplanted by Cell-Injection Therapy in a Feline Model.

Authors:  Cristina Bostan; Mathieu Thériault; Karolyn J Forget; Christelle Doyon; J Douglas Cameron; Stéphanie Proulx; Isabelle Brunette
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.